お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:前立腺がん治療装置の米国市場調査レポート:タイプ(放射線・手術・高密度焦点式超音波 (HIFU)・凍結療法)、エンドユーザー(病院・専門センター)別 -2030年までの業界分析と成長予測
市場調査レポート
商品コード
971139

前立腺がん治療装置の米国市場調査レポート:タイプ(放射線・手術・高密度焦点式超音波 (HIFU)・凍結療法)、エンドユーザー(病院・専門センター)別 -2030年までの業界分析と成長予測

U.S. Prostate Cancer Treatment Device Market Research Report: By Type (Radiation, Surgery, High-Intensity Focused Ultrasound, Cryotherapy), End User (Hospitals, Specialty Centers) - Industry Analysis and Growth Forecast to 2030

出版日: | 発行: Prescient & Strategic Intelligence Private Limited | ページ情報: 英文 124 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.15円
前立腺がん治療装置の米国市場調査レポート:タイプ(放射線・手術・高密度焦点式超音波 (HIFU)・凍結療法)、エンドユーザー(病院・専門センター)別 -2030年までの業界分析と成長予測
出版日: 2020年09月01日
発行: Prescient & Strategic Intelligence Private Limited
ページ情報: 英文 124 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国における前立腺がん治療装置の市場規模は、2019年の9590万米ドルから、2030年までに1億5710万米ドルへ達すると予測され、2020年から2030年の予測期間中、5.6%のCAGRで成長すると見込まれています。市場の成長を推進する主な要因は、毎年国内で記録されている前立腺がんの症例数の増加です。

当レポートでは、米国の前立腺がん治療装置市場について調査分析し、市場概要、市場成長への影響要因、市場規模と予測、セグメント別の市場分析、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 調査背景

  • 調査目的
  • 市場定義
  • 調査範囲
    • 市場セグメンテーション:タイプ別
    • 市場セグメンテーション:エンドユーザー別
    • 市場セグメンテーション:州別
    • 分析期間
    • 市場データ報告単位
  • 主要ステークホルダー

第2章 調査手法

  • 2次調査
  • 1次調査
  • ベースライン調査手法
  • 市場規模の推計
  • データ三角測量
  • 調査の前提条件

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 市場セグメントの定義
    • タイプ別
      • 放射線
      • 手術
      • HIFU
      • 凍結療法
      • その他
    • エンドユーザー別
      • 病院
      • 専門センター
      • その他
  • 市場力学
    • 動向
      • ロボット前立腺切除術の採用
      • 放射線治療技術の進化の加速
    • 促進要因
      • 技術の進歩
      • 前立腺がんの有病率の増加
      • 政府のイニシアチブ数の増加
      • 高齢者人口の急増
      • 市場予測に対する成長要因の影響分析
    • 抑制要因
      • 前立腺がん装置の承認期間が長い
      • 放射線療法に対する反応の分子予測因子を特定する際の課題
      • 市場予測に対する抑制要因の影響分析
    • 市場機会
      • 治療および患者エクスペリエンスを改善するためのポジショニング装置
  • 米国の前立腺がん治療装置市場に対するCOVID-19の影響
    • サプライサイド分析
    • デマンドサイド分析
  • ポーターのファイブフォース分析
  • 治療の比較
    • HIFU療法
    • 手術 vs. 放射線療法
    • 凍結療法
  • 装置の平均価格

第5章 米国の市場規模と予測

  • タイプ別
  • エンドユーザー別
  • 州別

第6章 競合情勢

  • 主要企業の競合ベンチマーキング
  • 市場における戦略的発展

第7章 企業プロファイル

  • SonaCare Medical LLC
  • EDAP TMS SA
  • Profound Medical Corporation
  • Eckert & Ziegler AG
  • HealthTronics Inc.
  • Boston Scientific Corporation
  • Elekta AB
  • Accuray Incorporated
  • Varian Medical Systems Inc.
  • Becton, Dickinson and Company
  • Intuitive Surgical Inc.
  • ViewRay Inc.
  • Provision Healthcare
  • Isoray Inc.
  • Theragenics Corporation

第8章 付録

図表

LIST OF TABLES

  • TABLE 1 ANALYSIS PERIOD OF THE STUDY
  • TABLE 2 RADIATION - CLINICAL TRIAL - 1
  • TABLE 3 RADIATION - CLINICAL TRIAL - 2
  • TABLE 4 RADIATION - CLINICAL TRIAL - 3
  • TABLE 5 RADIATION - CLINICAL TRIAL - 4
  • TABLE 6 RADIATION - CLINICAL TRIAL - 5
  • TABLE 7 RADIATION - CLINICAL TRIAL - 6
  • TABLE 8 RADIATION - CLINICAL TRIAL - 7
  • TABLE 9 RADIATION - CLINICAL TRIAL - 8
  • TABLE 10 SURGERY - CLINICAL TRIAL - 1
  • TABLE 11 SURGERY - CLINICAL TRIAL - 2
  • TABLE 12 SURGERY - CLINICAL TRIAL - 3
  • TABLE 13 SURGERY - CLINICAL TRIAL - 4
  • TABLE 14 SURGERY - CLINICAL TRIAL - 5
  • TABLE 15 SURGERY - CLINICAL TRIAL - 6
  • TABLE 16 SURGERY - CLINICAL TRIAL - 7
  • TABLE 17 HIFU - CLINICAL TRIAL - 1
  • TABLE 18 HIFU - CLINICAL TRIAL - 2
  • TABLE 19 HIFU - CLINICAL TRIAL - 3
  • TABLE 20 HIFU - CLINICAL TRIAL - 4
  • TABLE 21 HIFU - CLINICAL TRIAL - 5
  • TABLE 22 HIFU - CLINICAL TRIAL - 6
  • TABLE 23 HIFU - CLINICAL TRIAL - 7
  • TABLE 24 CRYOTHERAPY - CLINICAL TRIAL - 1
  • TABLE 25 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 26 RESTRAINT FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 27 HIFU - SONABLATE VS AMBLATHERM (SYSTEM SPECIFICATION)
  • TABLE 28 HIFU - SONABLATE VS AMBLATHERM (SAFETY FEATURE)
  • TABLE 29 PREFERECE OF TREATMENT - SURGERY VS RADIATION THERAPY
  • TABLE 30 PROCESS OF TREATMENT - SURGERY VS RADIATION THERAPY
  • TABLE 31 BENEFITS OF TREATMENT- SURGERY VS RADIATION THERAPY
  • TABLE 32 SIDE-EFFECTS AND DRAWBACKS OF TREATMENT- SURGERY VS RADIATION THERAPY
  • TABLE 33 AVERAGE PRICING OF DEVICES
  • TABLE 34 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, UNITS (2014-2019)
  • TABLE 35 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, UNITS (2020-2030)
  • TABLE 36 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, $M (2014-2019)
  • TABLE 37 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, $M (2020-2030)
  • TABLE 38 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY END USER, $M (2014-2019)
  • TABLE 39 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY END USER, $M (2020-2030)
  • TABLE 40 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY STATE, $M (2014-2019)
  • TABLE 41 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY STATE, $M (2020-2030)
  • TABLE 42 SONACARE MEDICAL LLC - AT A GLANCE
  • TABLE 43 EDAP TMS SA - AT A GLANCE
  • TABLE 44 EDAP TMS SA - KEY FINANCIAL SUMMARY
  • TABLE 45 PROFOUND MEDICAL CORPORATION - AT A GLANCE
  • TABLE 46 PROFOUND MEDICAL CORPORATION - KEY FINANCIAL SUMMARY
  • TABLE 47 ECKERT & ZIEGLER AG - AT A GLANCE
  • TABLE 48 ECKERT & ZIEGLER AG - KEY FINANCIAL SUMMARY
  • TABLE 49 HEALTHTRONICS INC. - AT A GLANCE
  • TABLE 50 BOSTON SCIENTIFIC CORPORATION - AT A GLANCE
  • TABLE 51 BOSTON SCIENTIFIC CORPORATION - KEY FINANCIAL SUMMARY
  • TABLE 52 ELEKTA AB - AT A GLANCE
  • TABLE 53 ELEKTA AB - KEY FINANCIAL SUMMARY
  • TABLE 54 ACCURAY INCORPORATED - AT A GLANCE
  • TABLE 55 ACCURAY INCORPORATED - KEY FINANCIAL SUMMARY
  • TABLE 56 VARIAN MEDICAL SYSTEMS INC. - AT A GLANCE
  • TABLE 57 VARIAN MEDICAL SYSTEMS INC. - KEY FINANCIAL SUMMARY
  • TABLE 58 BECTON, DICKINSON AND COMPANY - AT A GLANCE
  • TABLE 59 BECTON, DICKINSON AND COMPANY - KEY FINANCIAL SUMMARY
  • TABLE 60 INTUITIVE SURGICAL INC. - AT A GLANCE
  • TABLE 61 INTUITIVE SURGICAL INC. - KEY FINANCIAL SUMMARY
  • TABLE 62 VIEWRAY INC. - AT A GLANCE
  • TABLE 63 VIEWRAY INC. - KEY FINANCIAL SUMMARY
  • TABLE 64 PROVISION HEALTHCARE - AT A GLANCE
  • TABLE 65 ISORAY INC. - AT A GLANCE
  • TABLE 66 ISORAY INC. - KEY FINANCIAL SUMMARY
  • TABLE 67 THERAGENICS CORPORATION - AT A GLANCE

LIST OF FIGURES

  • FIG 1 RESEARCH SCOPE
  • FIG 2 RESEARCH METHODOLOGY
  • FIG 3 SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • FIG 4 SPLIT OF PRIMARY INFORMATION
  • FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
  • FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
  • FIG 7 SPLIT OF PRIMARY RESEARCH BY COMPANY AND DESIGNATION
  • FIG 8 DATA TRIANGULATION APPROACH
  • FIG 9 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET SUMMARY
  • FIG 10 BARGAINING POWER OF BUYERS
  • FIG 11 BARGAINING POWER OF SUPPLIERS
  • FIG 12 INTENSITY OF RIVALRY
  • FIG 13 THREAT OF NEW ENTRANTS
  • FIG 14 THREAT OF SUBSTITUTES
  • FIG 15 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET SNAPSHOT
  • FIG 16 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, SHARE & $M (2019)
  • FIG 17 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, UNITS (2014-2030)
  • FIG 18 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY TYPE, $M (2014-2030)
  • FIG 19 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY END USER, $M (2014-2030)
  • FIG 20 U.S. PROSTATE CANCER TREATMENT DEVICES MARKET, BY STATE, $M (2014-2030)
  • FIG 21 PRODUCT BENCHMARKING OF KEY PLAYERS
  • FIG 22 EDAP TMS SA - REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2019)
  • FIG 23 PROFOUND MEDICAL CORPORATION - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 24 ECKERT & ZIEGLER AG - REVENUE SPLIT BY SEGMENT AND BY GEOGRAPHY (2019)
  • FIG 25 BOSTON SCIENTIFIC CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 26 ELEKTA AB - REVENUE SPLIT BY GEOGRAPHY (2020)
  • FIG 27 ACCURAY INCOPORATED - REVENUE SPLIT BY GEOGRAPHY (2020)
  • FIG 28 VARIAN MEDICAL SYSTEMS INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 29 BECTON, DICKINSON AND COMPANY - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 30 INTUITIVE SURGICAL INC. - REVENUE SPLIT PRODUCT AND SERVICE AND GEOGRAPHY (2019)
  • FIG 31 VIEWRAY INC. - REVENUE SPLIT BY GEOGRAPHY (2019)
  • FIG 32 ISORAY INC. - REVENUE SPLIT BY GEOGRAPHY (2019)
目次
Product Code: LS12077

The U.S. prostate cancer treatment devices market attained a value of $95.9 million in 2019 and is predicted to grow at a CAGR of 5.6% between 2020 and 2030. According to the forecast of P&S Intelligence, a market research firm based in India, the market would reach a valuation of $157.1 million by 2030. The main factors driving the progress of the market are the increasing number of prostate cancer cases being recorded in the country every year.

The high prevalence of this diseases is predicted to push up the demand for various treatment devices and equipment such as cryotherapy, surgery, and radiotherapy in the future years, thereby causing the expansion of the U.S. prostate cancer treatment devices market. Apart from this, the increasing number of government initiatives being implemented in the country is also fueling the market advancement. The federal government spends a huge portion of the country's GDP on healthcare every year.

As per the reports of the National Health Expenditure Accounts (NHEA), healthcare expenditure in the U.S. increased by as much as 4.3% and reached $3.3 trillion in 2016. This percentage further grew to 5.4% in 2017. The soaring healthcare expenditure is making the management and treatment of various diseases more affordable than they were before, which is, in turn, fueling the expansion of the U.S. prostate cancer treatment devices market.

Thus, it can be said with certainty that the market would demonstrate substantial growth in the upcoming years, mainly because of the rising incidence of prostate cancer and the surging government spending on healthcare in the country.

Table of Contents

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Research Scope
    • 1.3.1 Market Segmentation by Type
    • 1.3.2 Market Segmentation by End User
    • 1.3.3 Market Segmentation by State
    • 1.3.4 Analysis Period
    • 1.3.5 Market Data Reporting Unit
      • 1.3.5.1 Value
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Split of Primary Research Information
    • 2.2.2 Breakdown of Primary Research by Industry Participant
    • 2.2.3 Breakdown of Primary Research by company type
    • 2.2.4 Breakdown of Primary Research by Company and Designation
  • 2.3 Baseline Methodology
  • 2.4 Market Size Estimation
  • 2.5 Data Triangulation
  • 2.6 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

  • 4.1 Definition of Market Segments
    • 4.1.1 By Type
      • 4.1.1.1 Radiation
        • 4.1.1.1.1 Clinical trials
      • 4.1.1.2 Surgery
        • 4.1.1.2.1 Clinical trials
      • 4.1.1.3 HIFU
        • 4.1.1.3.1 Clinical trials
      • 4.1.1.4 Cryotherapy
        • 4.1.1.4.1 Clinical trials
      • 4.1.1.5 Others
    • 4.1.2 By End User
      • 4.1.2.1 Hospitals
      • 4.1.2.2 Specialty centers
      • 4.1.2.3 Others
  • 4.2 Market Dynamics
    • 4.2.1 Trends
      • 4.2.1.1 Adoption of robotic prostatectomy
      • 4.2.1.2 Accelerating evolution in radiotherapy techniques
    • 4.2.2 Drivers
      • 4.2.2.1 Technological advancements
      • 4.2.2.2 Increasing prevalence of prostate cancer
      • 4.2.2.3 Rising number of government initiatives
      • 4.2.2.4 Surging geriatric population
      • 4.2.2.5 Impact analysis of drivers on market forecast
    • 4.2.3 Restraints
      • 4.2.3.1 Longer approval time for prostate cancer devices
      • 4.2.3.2 Challenges in identifying molecular predictors of response to radiotherapy
      • 4.2.3.3 Impact analysis of drivers on market forecast
    • 4.2.4 Opportunities
      • 4.2.4.1 Positioning devices to improve treatment and patient experience
  • 4.3 COVID-19 Impact on U.S. Prostate Cancer Treatment Devices Market
    • 4.3.1 Supply Side Analysis
    • 4.3.2 Demand Side Analysis
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Intensity of Rivalry
    • 4.4.4 Threat of New Entrants
    • 4.4.5 Threat of Substitutes
  • 4.5 Therapy Comparison
    • 4.5.1 HIFU Therapy
    • 4.5.2 Surgery Vs Radiation Therapy
    • 4.5.3 Cryotherapy
  • 4.6 Average Pricing of Devices

Chapter 5. U.S. Market Size and Forecast

  • 5.1 By Type
  • 5.2 By End User
  • 5.3 By State

Chapter 6. Competitive Landscape

  • 6.1 Product Benchmarking of Key Players
  • 6.2 Strategic Developments of Key Players
    • 6.2.1 Approvals and Product Launch
    • 6.2.2 Mergers and Acquisitions
    • 6.2.3 Other Developments

Chapter 7. Company Profiles

  • 7.1 SonaCare Medical LLC
    • 7.1.1 Business Overview
    • 7.1.2 Product and Service Offerings
  • 7.2 EDAP TMS SA
    • 7.2.1 Business Overview
    • 7.2.2 Product and Service Offerings
    • 7.2.3 Key Financial Summary
  • 7.3 Profound Medical Corporation
    • 7.3.1 Business Overview
    • 7.3.2 Product and Service Offerings
    • 7.3.3 Key Financial Summary
  • 7.4 Eckert & Ziegler AG
    • 7.4.1 Business Overview
    • 7.4.2 Product and Service Offerings
    • 7.4.3 Key Financial Summary
  • 7.5 HealthTronics Inc.
    • 7.5.1 Business Overview
    • 7.5.2 Product and Service Offerings
  • 7.6 Boston Scientific Corporation
    • 7.6.1 Business Overview
    • 7.6.2 Product and Service Offerings
    • 7.6.3 Key Financial Summary
  • 7.7 Elekta AB
    • 7.7.1 Business Overview
    • 7.7.2 Product and Service Offerings
    • 7.7.3 Key Financial Summary
  • 7.8 Accuray Incorporated
    • 7.8.1 Business Overview
    • 7.8.2 Product and Service Offerings
    • 7.8.3 Key Financial Summary
  • 7.9 Varian Medical Systems Inc.
    • 7.9.1 Business Overview
    • 7.9.2 Product and Service Offerings
    • 7.9.3 Key Financial Summary
  • 7.10 Becton, Dickinson and Company
    • 7.10.1 Business Overview
    • 7.10.2 Product and Service Offerings
    • 7.10.3 Key Financial Summary
  • 7.11 Intuitive Surgical Inc.
    • 7.11.1 Business Overview
    • 7.11.2 Product and Service Offerings
    • 7.11.3 Key Financial Summary
  • 7.12 ViewRay Inc.
    • 7.12.1 Business Overview
    • 7.12.2 Product and Service Offerings
    • 7.12.3 Key Financial Summary
  • 7.13 Provision Healthcare
    • 7.13.1 Business Overview
    • 7.13.2 Product and Service Offerings
  • 7.14 Isoray Inc.
    • 7.14.1 Business Overview
    • 7.14.2 Product and Service Offerings
    • 7.14.3 Key Financial Summary
  • 7.15 Theragenics Corporation
    • 7.15.1 Business Overview
    • 7.15.2 Product and Service Offerings

Chapter 8. Appendix

  • 8.1 Abbreviations
  • 8.2 Sources and References
  • 8.3 Related Reports
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.